Back to AZNView Full Landscape
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
9 competitors in Non-Small Cell Lung Cancer
REGNLibtayo
Phase 3MRTXMGCD265
Phase 2BNTXBNT327
Phase 2SNYoxaliplatine / gemcitabine / Vinorelbine
Phase 2GRTSGRT-C901
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/27/2018
Gefitinib Mylan
Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with activating mutations of EGFR TK.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts